Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab With or Without Tripterygium Glycosides for RA-Associated Pulmonary Fibrosis
ChiCTR2600116448Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of tocilizumab in rheumatoid arthritis (RA) and Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD) (2 arms), sponsored by The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine. Primary endpoint: High-Resolution Computed Tomography at week 24. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD)
Beyond the preview
Go deeper on ChiCTR2600116448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116448.